Myelodysplastic syndromes

被引：374

作者：

Ades, Lionel ^{[1
,2
]}

Itzykson, Raphael ^{[1
,2
]}

Fenaux, Pierre ^{[1
,2
]}

机构：

[1] Hop St Louis, AP HP, Hematol Serv, F-75475 Paris, France

[2] Univ Paris 07, F-75475 Paris, France

来源：

LANCET | 2014年 / 383卷 / 9936期

关键词：

ACUTE MYELOID-LEUKEMIA; PROGNOSTIC SCORING SYSTEM; STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; COLONY-STIMULATING FACTOR; TRANSFUSION-DEPENDENT PATIENTS; CONVENTIONAL CARE REGIMENS; IRON CHELATION-THERAPY; RANDOMIZED PHASE-II; REGULATORY T-CELLS;

D O I：

10.1016/S0140-6736(13)61901-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Myelodysplastic syndromes are clonal marrow stem-cell disorders, characterised by ineffective haemopoiesis leading to blood cytopenias, and by progression to acute myeloid leukaemia in a third of patients. 15% of cases occur after chemotherapy or radiotherapy for a previous cancer; the syndromes are most common in elderly people. The pathophysiology involves cytogenetic changes with or without gene mutations and widespread gene hypermethylation at advanced stages. Clinical manifestations result from cytopenias (anaemia, infection, and bleeding). Diagnosis is based on examination of blood and bone marrow showing blood cytopenias and hypercellular marrow with dysplasia, with or without excess of blasts. Prognosis depends largely on the marrow blast percentage, number and extent of cytopenias, and cytogenetic abnormalities. Treatment of patients with lower-risk myelodysplastic syndromes, especially for anaemia, includes growth factors, lenalidomide, and transfusions. Treatment of higher-risk patients is with hypomethylating agents and, whenever possible, allogeneic stem-cell transplantation.

引用

页码：2239 / 2252

页数：14

共 160 条

[1] Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies [J].

Ades, Lionel ;

Le Bras, Fabien ;

Sebert, Marie ;

Kelaidi, Charikleia ;

Lamy, Thierry ;

Dreyfus, Francois ;

Eclache, Virginie ;

Delaunay, Jacques ;

Bouscary, Didier ;

Visanica, Sorin ;

Turlure, Pascal ;

Bresler, Agnes Guerci ;

Cabrol, Marie-Paule ;

Banos, Anne ;

Blanc, Michel ;

Vey, Norbert ;

Delmer, Alain ;

Wattel, Eric ;

Chevret, Sylvie ;

Fenaux, Pierre .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (02) :213-218

[2]

AKSOY M, 1987, BRIT J IND MED, V44, P785

[3] Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study [J].

Alessandrino, Emilio Paolo ;

Della Porta, Matteo Giovanni ;

Bacigalupo, Andrea ;

Malcovati, Luca ;

Angelucci, Emanuele ;

Van Lint, Maria Teresa ;

Falda, Michele ;

Onida, Francesco ;

Bernardi, Massimo ;

Guidi, Stefano ;

Lucarelli, Barbarella ;

Rambaldi, Alessandro ;

Cerretti, Raffaella ;

Marenco, Paola ;

Pioltelli, Pietro ;

Pascutto, Cristiana ;

Oneto, Rosi ;

Pirolini, Laura ;

Fanin, Renato ;

Bosi, Alberto .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (03) :476-484

[4] Allogeneic marrow transplantation for Myelodysplastic syndrome with advanced disease morphology: A phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors [J].

Anderson, JE ;

Appelbaum, FR ;

Schoch, G ;

Gooley, T ;

Anasetti, C ;

Bensinger, WI ;

Bryant, E ;

Buckner, CD ;

Chauncey, T ;

Clift, RA ;

Deeg, HJ ;

Doney, K ;

Flowers, M ;

Hansen, JA ;

Martin, PJ ;

Matthews, DC ;

Nash, RA ;

Sanders, JE ;

Shulman, H ;

Sullivan, KM ;

Witherspoon, RP ;

Storb, R .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) :220-226

[5]

[Anonymous], 2005, HEMATOL ONCOL CLI S1

[6] Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation [J].

Armand, Philippe ;

Kim, Haesook T. ;

Cutler, Corey S. ;

Ho, Vincent T. ;

Koreth, John ;

Alyea, Edwin P. ;

Soiffer, Robert J. ;

Antin, Joseph H. .

BLOOD, 2007, 109 (10) :4586-4588

[7] Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey [J].

Arnold, R ;

de Witte, T ;

van Biezen, A ;

Hermans, J ;

Jacobsen, N ;

Runde, V ;

Gratwohl, A ;

Apperley, JF .

BONE MARROW TRANSPLANTATION, 1998, 21 (12) :1213-1216

[8] Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions [J].

Aziz, Athar ;

Baxter, E. Joanna ;

Edwards, Carol ;

Cheong, Clara Yujing ;

Ito, Mitsuteru ;

Bench, Anthony ;

Kelley, Rebecca ;

Silber, Yvonne ;

Beer, Philip A. ;

Chng, Keefe ;

Renfree, Marilyn B. ;

McEwen, Kirsten ;

Gray, Dionne ;

Nangalia, Jyoti ;

Mufti, Ghulam J. ;

Hellstrom-Lindberg, Eva ;

Kiladjian, Jean-Jacques ;

McMullin, Mary Frances ;

Campbell, Peter J. ;

Ferguson-Smith, Anne C. ;

Green, Anthony R. .

JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (05) :2169-2182

[9] A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome [J].

Barlow, Jillian L. ;

Drynan, Lesley F. ;

Hewett, Duncan R. ;

Holmes, Luke R. ;

Lorenzo-Abalde, Silvia ;

Lane, Alison L. ;

Jolin, Helen E. ;

Pannell, Richard ;

Middleton, Angela J. ;

Wong, See Heng ;

Warren, Alan J. ;

Wainscoat, James S. ;

Boultwood, Jacqueline ;

McKenzie, Andrew N. J. .

NATURE MEDICINE, 2010, 16 (01) :59-U93

[10] Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes [J].

Bejar, Rafael ;

Stevenson, Kristen E. ;

Caughey, Bennett A. ;

Abdel-Wahab, Omar ;

Steensma, David P. ;

Galili, Naomi ;

Raza, Azra ;

Kantarjian, Hagop ;

Levine, Ross L. ;

Neuberg, Donna ;

Garcia-Manero, Guillermo ;

Ebert, Benjamin L. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27) :3376-3382

← 1 2 3 4 5 6 7 8 9 10 →